Rajitha Alora Veedu1, Anita Balan2, Pramod Sankar S3. 1. Senior Resident, Government Dental College, Kozhikode, Kerala, India. Electronic address: raji_nbr@yahoo.co.in. 2. Professor and HOD, Department of OMR, Government Dental College, Kozhikode, Kerala, India. 3. Associate Professor in Dentistry, Malabar Cancer Centre, Thalassery, Kerala, India.
Abstract
OBJECTIVE: Numerous treatment modalities for oral submucous fibrosis (OSF) have been advocated over the years. However, its medical treatment is not yet fully standardized. This randomized double-blind trial assessed and compared the effects of two commonly used drugs, independently and in combination. METHODS:Forty-five patients were staged clinically and histopathologically for OSF and were randomly divided into three groups of 15 each by permuted block randomization. Each group received biweekly submucosal injections of hyaluronidase (1500 IU), dexamethasone (8 mg) or a combination of both (750 IU and 4 mg), respectively, for a period of 5 weeks. Improvement in pain upon opening, burning sensation, and tightness of mucosa as perceived by the patient, as well as improvement in mouth opening measured clinically were determined at the end of week 2, months 1, 2, 3, and 6 after the final injection. Results were compared and statistically analyzed using analysis of variance. RESULTS: Submucosal injection of hyaluronidase gave a quicker and better improvement of measured symptoms. CONCLUSIONS: Biweekly submucosal injection of hyaluronidase over a period of 5 weeks appears to be a viable treatment option for OSF.
RCT Entities:
OBJECTIVE: Numerous treatment modalities for oral submucous fibrosis (OSF) have been advocated over the years. However, its medical treatment is not yet fully standardized. This randomized double-blind trial assessed and compared the effects of two commonly used drugs, independently and in combination. METHODS: Forty-five patients were staged clinically and histopathologically for OSF and were randomly divided into three groups of 15 each by permuted block randomization. Each group received biweekly submucosal injections of hyaluronidase (1500 IU), dexamethasone (8 mg) or a combination of both (750 IU and 4 mg), respectively, for a period of 5 weeks. Improvement in pain upon opening, burning sensation, and tightness of mucosa as perceived by the patient, as well as improvement in mouth opening measured clinically were determined at the end of week 2, months 1, 2, 3, and 6 after the final injection. Results were compared and statistically analyzed using analysis of variance. RESULTS: Submucosal injection of hyaluronidase gave a quicker and better improvement of measured symptoms. CONCLUSIONS: Biweekly submucosal injection of hyaluronidase over a period of 5 weeks appears to be a viable treatment option for OSF.
Authors: Abdul Bari Memon; Aneela Atta Ur Rahman; Kashif Ali Channar; Muhammad Sohail Zafar; Naresh Kumar Journal: Int J Environ Res Public Health Date: 2022-02-05 Impact factor: 3.390